entertainment -WSS

entertainment

author：explore 2025-10-02 20:49:00 - browse：7

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

FDA warns medical device makers about rise in fabricated data

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

See how much Covid

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Researchers tackle phage therapy hurdles for wider adoption

hotspot

entertainment

Wikipedia

Apple is now the first public company to be valued at $3 trillion

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

State Dept. review finds Biden bears some blame for Afghanistan failures

Abridge raises $150m as clinical notes automation market heats up

Supreme Court strikes down use of affirmative action

ASCO: Palliative care found as helpful given virtually as in person

Guidelines to prevent youth baseball injuries need more muscle

As AI regulations shape up, health tech startups beg for clarity

BioMarin wins approval for gene therapy to treat hemophilia A

How to increase colonoscopy rates? Looks like an AI can help

knowledge

Abridge raises $150m as clinical notes automation market heats up

MD Anderson's Padmanee Sharma responds to research credit suit

The Pandemic Treaty must support building strong health systems

New study raises questions about niacin and heart health

Flagship Pioneering startup Sonata Therapeutics lays off 21

As AI regulations shape up, health tech startups beg for clarity

focus

explore

focus

focus